06-16-06

Express Mail No.: EV 456 922

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

plication

Meijer et al.

Confirmation No.

8852

erial No.

10/577,686

Art Unit

1626

Filed:

April 27, 2006

Examiner

To be Assigned

For:

INDIRUBIN-TYPE COMPOUNDS,

Attorney Docket No. 11181-025-999

COMPOSITIONS, AND METHODS FOR THEIR USE

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.56

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 and §1.97 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby direct the Examiner's attention to the references listed on the attached List of References Cited by Applicant.

Copies of publications A01-A09 listed on Form PTO-1449 are submitted herewith.

Identification of references listed on PTO Form 1449 is not to be construed as an admission of Applicants or attorneys for Applicants that such references are available as "prior art" against the subject application.

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.56

Serial No. 10/577,686

Page 2

Pursuant to 37 C.F.R. §1.97(b), since this information disclosure statement is being filed before the mailing of the first Office action on the merits, no fee is due in connection herewith. However, should the Patent Office determine otherwise, please charge the required fee to Jones Day deposit account no. 50-3013 (referencing 409742-999023); a duplicate of this sheet is enclosed.

Respectfully submitted,

Date:

June 14, 2006

54,398

Roger C. Rich

(Reg. No.)

For: Nikolaos C. George (Reg. No. 39,201)

JONES DAY

222 East 41st Street

New York, New York 10017

(212) 326-3939

								Sileet 1 C	/1 1	
						ATTY DOCKET NO. 11181-025-999		APPLICATION NO 10/577,686		
LIST OF R	EFE	RENCES CITED BY	APPLICA	NT	APPLICANT					
OIPE		(Use several sheets if r	Meijer et al.	Meijer et al.						
	40				FILING DATE		GROUP			
JUN 1 4 200	2				April 27, 20	06	1626			
3			U.S. PA	ATENT DO	CUMENTS					
INITIAL		DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING D		
				-		-				
			FOREIGN	PATENT	DOCUMENTS					
		DOCUMENT NUMBER	DATE		COUNTRY	CLASS	SUBCLASS	TRANSL	ATION	
		* * ** *** *** **** ******************						YES	NO	
	A01	WO01070231	9/27/01	PCT						
	A02	WO01037819	5/31/01	PCT						
	A03	WO05/041954	5/12/05	PCT				 		

	A04	Human Urine," The J. of Biol. Chem., 276(34):31475-31478.					
	A05						
	A06	Knockaert et al., 2004, "Independent Actions on Cyclin Dependent Kinases and Aryl Hydrocarbon Receptor Mediate the Antiproliferative Effects of Indirubins," Oncogene, 23:4400-4412.					
	A07	Leclerc et al., 2001, "Indirubins Inhibit Glycogen Syntahse Kinase-3beta and CDK5/P25, Two Protein Kinases Involved in Abnormal Tau Phosphorylation in Alzheimer's Disease," The J. of Biol. Chem., 276(1):251-260.					
	A08	Meijer et al., 2003, "GSK-3-Selective Inhibitors Derived From Tyrian Purple Indirubins," Chemis and Biol., 10(12):1255-1266.					
	A09 Polychronopoulos et al., 2004, "Structural Basis for the Synthesis of Indirubins as Potent and Selective Inhibitors of Glycogen Synthase Kinase-3 and Cyclin-Dependent Kinases," Journal of Med. Chem., 47:936-946.						
	_						
EXAMINER		DATE CONSIDERED					

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

CAJD-526821v1